10.1016/s1470-2045(16)00107-8 - Timing of androgen-deprivation therap...

This document has been corrected

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

10.1016/s1470-2045(16)00107-8

Published Online: 2016-06-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: Andrew Loblaw•Catherine D'Este•Gillian M Duchesne•Henry H Woo•Jeremy Millar•Julie K Bassett•Keen Hun Tai•Leo Ledwich•Madeleine King•Mark Frydenberg•Martin Stockler•Nigel Spry•Rodney A Syme•Roger Milne•Rosemary G Smith•Sandra Turner•Shawn Malone•Steven J Bowe

This document has been corrected

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

10.1016/s1470-2045(16)00107-8

Published Online: 2016-06-?

Journal: The Lancet Oncology

NOW

2017-09-01•Erratum

Correction to Lancet Oncol 2016; 17: 727–37

10.1016/s1470-2045(17)30575-2